Cardio Oncology Protecting Your Heart
Bridging the Gap in Cancer Care Through MyoHealth Score Guided Cardio Protection
Oncological life-saving therapies can cause subtle, progressive cardiac injury that often remains silent until significant LV dysfunction develops.
Cardiotoxicity often remains subclinical for months or years before symptoms appear, leading to heart failure for both current and long-term survival cancer patients.
MyoHealth® helps clinicians to risk stratify, detect and monitor cardiotoxicity enabling timely cardioprotective intervention and long-term surveillance.
Clinical Applications Across the Cancer Care Continuum
- Pre-Treatment Baseline:
- Establishes a baseline risk score of cancer related cardiotoxicity before initiating therapy.
- During Therapy:
- Detects LV intramyocardial dysfunction to implement cardio protection for heart function recovery.
- Post-Cancer Treatment and survivors:
- Surveillance of MyoHealth Score to monitor progressive cardiac dysfunction over time
August 12, 2023
Journal of Clinical Medicine
Advances in cancer therapies have led to a global improvement in patient survival rates. Nevertheless, the price to pay is a concomitant increase in cardiovascular (CV) morbidity and mortality in this population. Increased inflammation and disturbances of the immune system are shared by both cancer and CV diseases.
Advances in cancer therapies have led to a global improvement in patient survival rates. Nevertheless, the price to pay is a concomitant increase in cardiovascular (CV) morbidity and mortality in this population. Increased inflammation and disturbances of the immune system are shared by both cancer and CV diseases. Immunological effects of anti-cancer treatments occur with both conventional chemotherapy and, to a greater extent, with novel biological therapies such as immunotherapy. For these reasons, there is growing interest in the immune system and its potential role at the molecular level in determining cardiotoxicity. Early recognition of these detrimental effects could help in identifying patients at risk and improve their oncological management. Non-invasive imaging already plays a key role in evaluating baseline CV risk and in detecting even subclinical cardiac dysfunction during surveillance. The aim of this review is to highlight the role of advanced cardiovascular imaging techniques in the detection and management of cardiovascular complications related to cancer treatment.
June 15, 2021
Circulation: Cardiovascular Imaging
This publication features key outcome data from the PREFECT study demonstrating MyoStrain’s ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
August 31, 2019
Abstract at ESC Congress 2019
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
2025
Toro-Salazar, O. et al.
April 7, 2024
Lenihan, D. et al.
August 9, 2022
Lenihan, D. et al.